2020-12-02

Camurus announces that Braeburn receives Complete Response Letter for Brixadi for opioid use disorder in the US

Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.

Read the full press release: https://www.camurus.com/

Stefan Persson – New President and CEO

Martin Jonsson´s successor as President and CEO of the Sandberg Development Group has now been appointed and it is w…

2021-07-15

Camurus Interim Report for the second quarter 2021

Today, Camurus' interim report for the second quarter 2021 was published. "It was a positive second quarter with sig…

2021-05-20

Camurus receives Carnegie Sustainability Award 2021

Camurus has been awarded with the Carnegie Sustainability Award 2021 in the category small-cap, presented at the Car…

2021-04-21

Camurus Annual Report for 2020

Camurus Annual Report for 2020 is now available at the company's website.

2021-02-19

Granuldisk finalist at Malmö Näringslivsgala

Granuldisk was selected as one of the finalists presented by Malmö Näringslivsgala, a business gala for companies lo…